A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.
Recruiting
Observational Study
Parkinson Disease
Parkinson's Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 50 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 6 (estimated)
- Sponsor
- Innopeutics Corporation · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.
* Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the stud…
Contacts